for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novo Nordisk A/S (ADR)

NVO

Latest Trade

106.01USD

Change

0.00(0.00%)

Volume

1,255

Today's Range

--

 - 

--

52 Week Range

63.22

 - 

107.24

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
106.01
Open
0.00
Volume
1,255
3M AVG Volume
21.85
Today's High
--
Today's Low
--
52 Week High
107.24
52 Week Low
63.22
Shares Out (MIL)
2,272.06
Market Cap (MIL)
187,614.80
Forward P/E
33.24
Dividend (Yield %)
1.39

Next Event

Q3 2021 Novo Nordisk A/S Earnings Release

Latest Developments

More

French company BIOCORP forms partnership with Novo Nordisk on 'smart pens' to help those with diabetes

Novo Nordisk To Pay $100 Mln In Settlement Agreement

Exscientia Files For U.S. IPO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novo Nordisk A/S (ADR)

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Industry

Biotechnology & Drugs

Contact Info

Novo Alle 1

2880

Denmark

+45.44.448888

https://www.novonordisk.com/

Executive Leadership

Helge Lund

Independent Chairman of the Board

Lars Fruergaard Joergensen

President, Chief Executive Officer

Jeppe Christiansen

Vice Chairman of the Board

Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

Maziar Mike Doustdar

Executive Vice President, International Operations

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2018

115.2K

2019

122.0K

2020

126.9K

2021(E)

137.1K
EPS (DKK)

2018

16.420

2019

16.380

2020

18.010

2021(E)

20.267
Price To Earnings (TTM)
35.41
Price To Sales (TTM)
9.23
Price To Book (MRQ)
23.47
Price To Cash Flow (TTM)
23.75
Total Debt To Equity (MRQ)
20.99
LT Debt To Equity (MRQ)
19.01
Return on Investment (TTM)
57.56
Return on Equity (TTM)
30.16

Latest News

Latest News

Novo Nordisk's new weight-loss drug getting a boost from pandemic -CEO

The pandemic is pushing more people to seek treatment for obesity, Novo Nordisk's top boss said on Thursday, referring to strong sales of the newly launched drug, Wegovy, which helped the drugmaker raise its earnings forecast for the full year.

Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion

Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp's experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday.

Risk of patient overlap between Wegovy and Saxenda obesity drugs, Novo says

Novo Nordisk's new obesity drug Wegovy, far more efficient at causing weight loss in patients than similar drugs on the market, could capture sales of its existing obesity treatment Saxenda in the United States, the firm said on Monday.

U.S. FDA approves Novo Nordisk's semaglutide as obesity treatment

The U.S. Food and Drug Administration (FDA) on Friday approved Danish drugmaker Novo Nordisk's once-weekly semaglutide drug as a treatment for obesity, a condition that affects nearly 70% of American adults.

Novo Nordisk semaglutide gets U.S. FDA approval for obesity treatment

Denmark's Novo Nordisk on Friday said the U.S. Food and Drug Administration (FDA) had approved its semaglutide drug as a treatment for obesity.

Novo Nordisk lifts guidance after first quarter beats expectations

Denmark's Novo Nordisk raised its sales and profit forecasts on Wednesday after beating first-quarter earnings expectations, lifting shares in the world's biggest maker of diabetes drugs.

Novo Nordisk owner, Danish government in talks about vaccine production

The foundation that controls Danish drug maker Novo Nordisk said on Monday it is in preliminary talks with the government about establishing local vaccine production.

UPDATE 2-Diabetes drugmaker Novo Nordisk upbeat on 2021, sees Biden boost

Diabetes drugmaker Novo Nordisk forecast a rise in underlying sales and profit for 2021 on Wednesday and said it expected more Americans to get access to its drugs under the new Biden administration.

Novo Nordisk to start late-stage trial of semaglutide to treat Alzheimer's

Diabetes drugmaker Novo Nordisk will start a late-stage clinical trial to test its semaglutide drug as a treatment for early Alzheimer's disease, it said on Wednesday.

Novo Nordisk to boost pill-form diabetic drugs with $1.8 billion deal

Diabetes drug maker Novo Nordisk said on Friday it had agreed a $1.8 billion deal to acquire Emisphere Technologies, giving it control of a pill technology that it hopes will broaden sales to diabetics with an aversion to shots.

Denmark's Novo Nordisk to buy Emisphere Technologies in $1.8 billion deal

Danish diabetes drug maker Novo Nordisk will acquire U.S. Emisphere Technologies, which specialises in developing orally administered versions of drugs, in a deal totalling $1.8 billion, it said on Friday.

Novo Nordisk sales rise as more diabetics seek treatment

Drugmaker Novo Nordisk <NOVOb.CO> has seen a gradual recovery in the number of diabetics starting treatment, it said on Friday after reporting 2% sales growth in the third quarter.

European stocks rise on upbeat forecasts from Pandora, Novo Nordisk

European stock markets gained on Friday on rosy earnings forecasts from retailers Pandora and Zalando as well as drugmaker Novo Nordisk, with investors keeping an eye out for signs of fresh U.S. stimulus.

Novo Nordisk tweaks outlook higher after pandemic sales hit

Diabetes drug maker Novo Nordisk <NOVOb.CO> raised its full-year earnings outlook slightly on Thursday as it managed to offset stagnant sales with cost cuts during the coronavirus crisis.

BRIEF-Novo Nordisk: Rybelsus Approved In Japan

* REG-RYBELSUS® APPROVED IN JAPAN FOR THE TREATMENT OF TYPE 2 DIABETES

BRIEF-Novo Nordisk Successfully Completes Am833 Phase 2 Trial And Phase 1 Combination Trial

* REG-NOVO NORDISK SUCCESSFULLY COMPLETES AM833 PHASE 2 TRIAL AND PHASE 1 COMBINATION TRIAL WITH AM833 AND SEMAGLUTIDE IN OBESITY

BRIEF-Novo Nordisk: Semaglutide 2.4 Mg Shows Superior Weight Loss Versus Placebo In Phase 3 Trials

* REG-SEMAGLUTIDE 2.4 MG SHOWS SUPERIOR WEIGHT LOSS VERSUS PLACEBO IN THE PHASE 3 TRIALS STEP 2 AND STEP 3, THEREBY SUCCESSFULLY COMPLETING THE PROGRAMME

BRIEF-HBM Healthcare Investments: Novo Nordisk Buys Portfolio Company

* NOVO NORDISK ACQUIRES HBM PORTFOLIO COMPANY CORVIDIA THERAPEUTICS FOR UP TO USD 2.1 BILLION IN CASH Source text for Eikon: Further company coverage: (Gdansk Newsroom)

Novo Nordisk expands into cardiovascular disease with $725 million deal

Novo Nordisk <NOVOb.CO> has agreed to buy AstraZeneca spin-off Corvidia Therapeutics for an initial $725 million as the world's largest diabetes drugmaker seeks to expand into cardiovascular disease treatments.

Novo Nordisk expands in cardiovascular disease with $725 mln deal

Novo Nordisk has agreed to buy AstraZeneca spin-off Corvidia Therapeutics for an initial $725 million as the world's largest diabetes drugmaker seeks to expand in cardiovascular disease.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up